Moffitt Cancer Center's 13th Annual Ted Couch Cancer Research Lecture will feature Brian J. Druker, M.D., director of the Oregon Health & Science University's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research and investigator of the Howard Hughes Medical Institute, at 4 p.m. on May 26, in the Vincent A. Stabile Research Building, 12902 Magnolia Drive.

Druker is widely recognized for his research studying the regulation of the growth of cancer cells and the practical application of cancer therapies. In collaboration with Novartis, his laboratory performed the pre-clinical studies that were instrumental in the development of Gleevec (Imatinib) - a drug that targets chronic myeloid leukemia (CML) and which is also FDA approved for gastrointestinal stromal tumors and five other cancers.

Druker has received numerous prestigious awards for his research, including the American Association for Cancer Research - Richard and Hinda Rosenthal Award; the American Society of Hematology's Dameshek Prize; the American Society of Clinical Oncology's Karnofsky Award and the 2009 Lasker-Debakey Award for Clinical Medical Research.

A reception with refreshments will follow his presentation, "The End of Cancer Is Within Reach." Please RSVP by May 23 to 1-888-MOFFITT (1-888-663-3488).

Source:
Moffitt Cancer Center

View drug information on Gleevec.